Virus-host Interactions in Carcinogenesis of Epstein-Barr Virus-associated Gastric Carcinoma: Potential Roles of Lost ARID1A Expression in Its Early Stage
Overview
Authors
Affiliations
Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) is a distinct molecular subtype of gastric cancer characterized by viral infection and cellular abnormalities, including loss of AT-rich interaction domain 1A (ARID1A) expression (lost ARID1A). To evaluate the significance of lost ARID1A in the development of EBVaGC, we performed in situ hybridization of EBV-encoded RNA (EBER) and immunohistochemistry of ARID1A in the non-neoplastic gastric mucosa and intramucosal cancer tissue of EBVaGC with in vitro infection analysis of ARID1A-knockdown and -knockout gastric cells. Screening of EBER by in situ hybridization revealed a frequency of approximately 0.2% EBER-positive epithelial cells in non-neoplastic gastric mucosa tissue samples. Six small foci of EBV-infected epithelial cells showed two types of histology: degenerated (n = 3) and metaplastic (n = 3) epithelial cells. ARID1A was lost in the former type. In intramucosal EBVaGC, there were ARID1A-lost (n = 5) and -preserved tumors (n = 7), suggesting that ARID1A-lost carcinomas are derived from ARID1A-lost precursor cells in the non-neoplastic mucosa. Lost ARID1A was also observed in non-neoplastic mucosa adjacent to an ARID1A-lost EBVaGC. In vitro experiments using siRNA knockdown and the CRISPR/Cas9-knockout system demonstrated that transient reduction or permanent loss of ARID1A expression markedly increased the efficiency of EBV infection to stomach epithelial cells. Taken together, lost ARID1A plays a role in initiating EBV-driven carcinogenesis in stomach epithelial cells, which develop to a distinct subtype of EBVaGC within the proper mucosal layer. Lost ARID1A is one of the constituents of virus-host interactions in the carcinogenesis of EBVaGC.
Angelico G, Attanasio G, Colarossi L, Colarossi C, Montalbano M, Aiello E Cancers (Basel). 2024; 16(11).
PMID: 38893181 PMC: 11171396. DOI: 10.3390/cancers16112062.
Recent Advances on the Molecular Mechanism and Clinical Trials of Venous Thromboembolism.
Huang S, Xin H, Wang X, Feng G, Wu F, Feng Z J Inflamm Res. 2023; 16:6167-6178.
PMID: 38111686 PMC: 10726951. DOI: 10.2147/JIR.S439205.
The effects of ARID1A mutation in gastric cancer and its significance for treatment.
Lu S, Duan R, Cong L, Song Y Cancer Cell Int. 2023; 23(1):296.
PMID: 38008753 PMC: 10676575. DOI: 10.1186/s12935-023-03154-8.
Iizasa H, Kartika A, Fekadu S, Okada S, Onomura D, Ahmad Wadi A World J Gastroenterol. 2022; 28(44):6249-6257.
PMID: 36504553 PMC: 9730441. DOI: 10.3748/wjg.v28.i44.6249.
Serological and Molecular Characterization of Hepatitis B Virus Infection in Gastric Cancer.
Li M, Wu S, Luo H, Niu J, Yan Y, Fang Y Front Cell Infect Microbiol. 2022; 12:894836.
PMID: 35592651 PMC: 9113707. DOI: 10.3389/fcimb.2022.894836.